SCHEMBL6325602

SCHEMBL6325602

CNc1nc2ccccc2n1CC(=O)c1ccccc1

nearest known ligand 0.97

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.70
TSHR P16473 4/20 0.60
CYP1A2 P05177 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
KDM4E B2RXH2 2/20 0.57
CTSD P07339 1/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
NPSR1 Q6W5P4 3/20 0.57
HTT P42858 1/20 0.57
USP2 O75604 1/20 0.57
RAB9A P51151 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
ALDH1A1 P00352 1/20 0.56
POLB P06746 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8565487 0.83 SMN1; SMN2 (1.00) SMN1; SMN2TSHRMEN1KMT2ANPSR1
Bromide SCHEMBL8864660 0.82 SMN1; SMN2 (0.97) SMN1; SMN2TSHRMEN1KMT2ANPSR1
SCHEMBL8563635 0.82 SMN1; SMN2 (0.80) SMN1; SMN2TSHRCYP1A2CYP2D6CYP2C9
Hydrochloric Acid SCHEMBL8864540 0.81 SMN1; SMN2 (0.78) SMN1; SMN2TSHRCYP1A2CYP2D6CYP2C9
SCHEMBL9568271 0.81 SMN1; SMN2 (0.86) SMN1; SMN2TSHRNPSR1USP2ALDH1A1
Bromide SCHEMBL8864504 0.80 SMN1; SMN2 (0.84) SMN1; SMN2TSHRNPSR1USP2ALDH1A1
SCHEMBL28890678 0.76 KDM4E (0.56) SMN1; SMN2TSHRKDM4EMEN1KMT2A
SCHEMBL27926418 0.75 CYP1A2 (0.68) SMN1; SMN2TSHRCYP1A2CYP2D6CYP2C9
SCHEMBL1520208 0.75 KDM4E (0.57) SMN1; SMN2TSHRCYP1A2CYP2D6CYP2C19
SCHEMBL10464937 0.75 HTT (0.56) SMN1; SMN2CYP1A2CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050272036-A1 Ketones ASTRAZENECA AB (SE) 2005-12-08 US disclosed
US-6946565-B2 Process for the preparation of an indole derivative SMITHKLINE BEECHAM PLC (GB) 2005-09-20 US disclosed
US-6583294-B2 Reacting 3-chloro-3-carboxylate indole with 3-chloropropanol in presence of such as trichloroacetic acid to produce methyl 2-(3-chloropropoxy)-indole-3-carboxylate in high yield SMITHKLINE BEECHAM P.L.C. (GB) 2003-06-24 US disclosed
US-20030114684-A1 Preparation of methyl 2-(3-chloropropoxy)indole-3-carboxylate by reacting 3-chloro-3-carboxylate indole compound with 3-chloropropanol in presence of acid having pKa of 0-2 SMITHKLINE BEECHAM PLC 2003-06-19 US disclosed
US-20030083506-A1 PROCESS FOR THE PREPARATION OF AN INDOLE DERIVATIVE SMITHKLINE BEECHAM P.L.C. 2003-05-01 US disclosed
US-20020091271-A1 Process for the preparation of an indole derivative SMITHKLINE BEECHAM PLC 2002-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083506-A1 PROCESS FOR THE PREPARATION OF AN INDOLE DERIVATIVE PRKD3, COMT, IDO1 SMN1; SMN2 4842/4885TSHR 1840/4885CYP1A2 295/4885
US-20030114684-A1 Preparation of methyl 2-(3-chloropropoxy)indole-3-carboxylate by reacting 3-chloro-3-carboxylate indole compound with 3-chloropropanol in presence of acid having pKa of 0-2 HTR3C, HTR3A, PRKD3 SMN1; SMN2 4839/4885TSHR 1975/4885CYP1A2 488/4885
US-20020091271-A1 Process for the preparation of an indole derivative PRKD3, COMT, IDO1 SMN1; SMN2 4842/4885TSHR 1840/4885CYP1A2 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.